This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics. CA Cancer J Clin 2002; 2005: 74-108. doi: 10.3322/canjclin.55.2.74ParkinDMBrayFFerlayJPisaniPGlobal cancer statistics200220057410810.3322/canjclin.55.2.7415761078Open DOISearch in Google Scholar
Moghimi-Dehkordi B, Safaee A. An overview of colorectal cancer survival rates and prognosis in Asia. World J Gastrointest Oncol 2012; 4: 71-5. doi: 10.4251/wjgo.v4.i4.71Moghimi-DehkordiBSafaeeAAn overview of colorectal cancer survival rates and prognosis in Asia2012471510.4251/wjgo.v4.i4.71333438222532879Open DOISearch in Google Scholar
Wolpin BM, Mayer RJ. Systemic treatment of colorectal cancer. Gastroenterology 2008; 134: 1296-310. doi: 10.1053/j.gastro.2008.02.098WolpinBMMayerRJSystemic treatment of colorectal cancer2008134129631010.1053/j.gastro.2008.02.098252883218471507Open DOISearch in Google Scholar
Kelly H, Goldberg RM. Systemic therapy for metastatic colorectal cancer: current options, current evidence. J Clin Oncol 2005; 23: 4553-60. doi: 10.1200/JCO.2005.17.749KellyHGoldbergRMSystemic therapy for metastatic colorectal cancer: current options, current evidence20052345536010.1200/JCO.2005.17.74916002847Open DOISearch in Google Scholar
Bos JL, Fearon ER, Hamilton SR, Verlaan-de Vries M, van Boom JH, van der Eb AJ, et al. Prevalence of RAS mutations in human colorectal cancers. Nature 1987; 327: 293-7. doi: 10.1038/327293a0BosJLFearonERHamiltonSRVerlaan-deVries Mvan BoomJHvan derEb AJet alPrevalence of RAS mutations in human colorectal cancers1987327293710.1038/327293a03587348Open DOISearch in Google Scholar
Finkelstein SD, Sayegh R, Christensen S, Swalsky PA. Genotypic classification of colorectal adenocarcinoma. Cancer 1993; 71: 3827-38. 10.1002/1097-0142(19930615)71:12<3827::aid-cncr2820711207>3.0.co;2-nFinkelsteinSDSayeghRChristensenSSwalskyPAGenotypic classification of colorectal adenocarcinoma19937138273810.1002/1097-0142(19930615)71:12<3827::aid-cncr2820711207>3.0.co;2-n10.1002/1097-0142(19930615)71:12<3827::AID-CNCR2820711207>3.0.CO;2-NSearch in Google Scholar
Boughdady IS, Kinsella AR, Haboubi NY, Schofield PF. K-ras gene mutations in adenomas and carcinomas of the colon. Surg Oncol 1992; 1: 275-82. doi: 10.1016/0960-7404(92)90087-2BoughdadyISKinsellaARHaboubiNYSchofieldPFK-ras gene mutations in adenomas and carcinomas of the colon199212758210.1016/0960-7404(92)90087-2Open DOISearch in Google Scholar
Heinemann V, Stintzing S, Kirchner T, Boeck S, Jung A. Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR. Cancer Treat Rev 2009; 35: 262-71. doi: 10.1016/j.ctrv.2008.11.005HeinemannVStintzingSKirchnerTBoeckSJungAClinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR2009352627110.1016/j.ctrv.2008.11.005Open DOISearch in Google Scholar
Gong J, Cho M, Sy M, Salgia R, Fakih M. Molecular profiling of metastatic colorectal tumors using next-generation sequencing: a single-institution experience. Oncotarget 2017; 8: 42198-213. doi: 10.18632/oncotarget.15030GongJChoMSyMSalgiaRFakihMMolecular profiling of metastatic colorectal tumors using next-generation sequencing: a single-institution experience201784219821310.18632/oncotarget.15030Open DOISearch in Google Scholar
Ibrahim T, Saer-Ghorra C, Trak-Smayra V, Nadiri S, Yazbeck C, Baz M, et al. Molecular characteristics of colorectal cancer in a Middle Eastern population in a single institution. Ann Saudi Med 2018; 38: 251-9. doi: 10.5144/0256-4947.2018.251IbrahimTSaer-GhorraCTrak-SmayraVNadiriSYazbeckCBazMet alMolecular characteristics of colorectal cancer in a Middle Eastern population in a single institution201838251910.5144/0256-4947.2018.251Open DOISearch in Google Scholar
Abubaker J, Bavi P, Al-Haqawi W, Sultana M, Al-Harbi S, Al-Sanea N, et al. Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma. J Pathol 2009; 219: 435-45. doi: 10.1002/path.2625AbubakerJBaviPAl-HaqawiWSultanaMAl-HarbiSAl-SaneaNet alPrognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma20092194354510.1002/path.262519824059Open DOISearch in Google Scholar
Zahrani A, Kandil M, Badar T, Abdelsalam M, Al-Faiar A, Ismail A. Clinico-pathological study of K-ras mutations in colorectal tumors in Saudi Arabia. Tumori 2014; 100: 75-9. doi: 10.1700/1430.15819ZahraniAKandilMBadarTAbdelsalamMAl-FaiarAIsmailAClinico-pathological study of K-ras mutations in colorectal tumors in Saudi Arabia201410075910.1700/1430.1581924675495Open DOISearch in Google Scholar
Murtaza B, Bibi A, Rashid M, Khan Y, Chaudri M, Shakoori A. Spectrum of KRAS mutations in Pakistani colorectal cancer patients. Braz J Med Biol Res 2014; 47: 35-41. doi: 10.1590/1414-431X20133046MurtazaBBibiARashidMKhanYChaudriMShakooriASpectrum of KRAS mutations in Pakistani colorectal cancer patients201447354110.1590/1414-431X20133046393297124519090Open DOISearch in Google Scholar
Segal G, Liebermann N, Klang S, Siegelmann-Daniel N, Beit-Or A, Klien B, et al. Identification of KRAS mutations in colorectal cancer patients in Israel. Harefuah 2011; 150: 447-50.SegalGLiebermannNKlangSSiegelmann-DanielNBeit-OrAKlienBet alIdentification of KRAS mutations in colorectal cancer patients in Israel201115044750Search in Google Scholar
Marchoudi N, Joutei HAH, Jouali F, Fekkak J, Rhaissi H. Distribution of KRAS and BRAF mutations in Moroccan patients with advanced colorectal cancer. Pathol Biol 2013; 61: 273-6. doi: 10.1016/j.patbio.2013.05.004MarchoudiNJouteiHAHJoualiFFekkakJRhaissiHDistribution of KRAS and BRAF mutations in Moroccan patients with advanced colorectal cancer201361273610.1016/j.patbio.2013.05.00423849768Open DOISearch in Google Scholar
Chaiyapan W, Duangpakdee P, Boonpipattanapong T, Kanngern S, Sangkhatthat S. Somatic mutations of K-RAS and BRAF in Thai colorectal cancer and their prognostic value. Asian Pac J Cancer Prev 2013; 14: 329-32. doi: 10.7314/apjcp.2013.14.1.329ChaiyapanWDuangpakdeePBoonpipattanapongTKanngernSSangkhatthatSSomatic mutations of K-RAS and BRAF in Thai colorectal cancer and their prognostic value2013143293210.7314/apjcp.2013.14.1.32923534748Open DOISearch in Google Scholar
Kafatos G, Niepel D, Lowe K, Jenkins-Anderson S, Westhead H, Garawin T, et al. RAS mutation prevalence among patients with metastatic colorectal cancer : a meta-analysis of real-world data. Biomark Med 2017; 11: 751-60. doi: 10.2217/bmm-2016-0358KafatosGNiepelDLoweKJenkins-AndersonSWestheadHGarawinTet alRAS mutation prevalence among patients with metastatic colorectal cancer : a meta-analysis of real-world data2017117516010.2217/bmm-2016-0358636777828747067Open DOISearch in Google Scholar
Kwak MS, Cha JM, Cho YH, Kim SH, Yoon JY, Jeon JW, et al. Clinical predictors for KRAS codon 13 mutations in patients with colorectal cancer. J Clin Gastroenterol 2018; 52: 431-6. doi: 10.1097/MCG.0000000000000809KwakMSChaJMChoYHKimSHYoonJYJeonJWet alClinical predictors for KRAS codon 13 mutations in patients with colorectal cancer201852431610.1097/MCG.000000000000080928277374Open DOISearch in Google Scholar
Dobre M, Dinu DE, Panaitescu E, Birla RE, Iosif CI, Boeriu M, et al. KRAS gene mutations – prognostic factor in colorectal cancer? Rom J Morphol Embryol 2015; 56(2 Suppl): 671-8. PMID: 26429158DobreMDinuDEPanaitescuEBirlaREIosifCIBoeriuMet alKRAS gene mutations – prognostic factor in colorectal cancer?2015562 Suppl6718PMID: 2642915810.26226/morressier.57a2f938d462b8028d88feffSearch in Google Scholar
Van Cutsem, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408-17. doi: 10.1056/NEJMoa0805019VanCutsemKöhneCHHitreEZaluskiJChangChien CRMakhsonAet alCetuximab and chemotherapy as initial treatment for metastatic colorectal cancer200936014081710.1056/NEJMoa080501919339720Open DOISearch in Google Scholar
Bokemeyer C, Bondarenko I, Hartmann JT, de Braud F, Schuch G, Zubel A, et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 2011; 22: 1535-46. doi: 10.1093/annonc/mdq632BokemeyerCBondarenkoIHartmannJTde BraudFSchuchGZubelAet alEfficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study20112215354610.1093/annonc/mdq63221228335Open DOISearch in Google Scholar
Pentheroudakis G, Kotoula V, De Roock W, Kouvatseas G, Papakostas P, Makatsoris T, et al. Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/ RAF, PIK3CA genotypes. BMC Cancer 2013; 13: 49. doi: 10.1186/1471-2407-13-49PentheroudakisGKotoulaVDe RoockWKouvatseasGPapakostasPMakatsorisTet alBiomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/ RAF, PIK3CA genotypes2013134910.1186/1471-2407-13-49359969723374602Open DOISearch in Google Scholar
Mao C, Yang ZY, Hu XF, Chen Q, Tang JL. PIK3CA exon 20 mutations as a potential biomarker for resistance to anti- EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis. Ann Oncol 2012; 23: 1518-25. doi: 10.1093/annonc/mdr464MaoCYangZYHuXFChenQTangJLPIK3CA exon 20 mutations as a potential biomarker for resistance to anti- EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis20122315182510.1093/annonc/mdr46422039088Open DOISearch in Google Scholar
Brulé SY, Jonker DJ, Karapetis CS, O’Callaghan CJ, Moore MJ, Wong R, et al. Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17. Eur J Cancer 2015; 51: 1405-14. doi: 10.1016/j.ejca.2015.03.015BruléSYJonkerDJKarapetisCSO’CallaghanCJMooreMJWongRet alLocation of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.1720155114051410.1016/j.ejca.2015.03.01525979833Open DOISearch in Google Scholar
Petrelli F, Tomasello G, Borgonov K, Ghidini M, Turati L, Dallera P, et al. Prognostic survival associated with left-sided vs right-sided colon cancer. A systematic review and meta-analysis. JAMA Oncol 2016; 3: 211-19. doi: 10.1001/jamaoncol.2016.4227PetrelliFTomaselloGBorgonovKGhidiniMTuratiLDalleraPet alPrognostic survival associated with left-sided vs right-sided colon cancer A systematic review and meta-analysis201632111910.1001/jamaoncol.2016.422727787550Open DOISearch in Google Scholar
Tejpar S, Celik I, Schlichting M, Sartorius U, Bokemeyer C, Van Cutsem E. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. J Clin Oncol 2012; 30: 3570-7. doi: 10.1200/ JCO.2012.42.2592TejparSCelikISchlichtingMSartoriusUBokemeyerCVanCutsem EAssociation of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab2012303570710.1200/ JCO.2012.42.2592Open DOISearch in Google Scholar
Chen J, Ye Y, Sun H, Shi G. Association between KRAS codon 13 mutations and clinical response to anti-EGFR treatment in patients with metastatic colorectal cancer: results from a meta-analysis. Cancer Chemother Pharmacol 2013; 71: 265-72. doi: 10.1007/s00280-012-2005-9ChenJYeYSunHShiGAssociation between KRAS codon 13 mutations and clinical response to anti-EGFR treatment in patients with metastatic colorectal cancer: results from a meta-analysis2013712657210.1007/s00280-012-2005-923090619Open DOISearch in Google Scholar
Peeters M, Douillard JY, Van Cutsem E, Siena S, Zhang K, Williams R, et al. Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab. J Clin Oncol 2013; 31: 759-65. doi: 10.1200/ JCO.2012.45.1492PeetersMDouillardJYVanCutsem ESienaSZhangKWilliamsRet alMutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab2013317596510.1200/ JCO.2012.45.1492Open DOISearch in Google Scholar
Andreyev HJ, Norman AR, Cunningham D, Oates JR, Clarke PA. Kirsten Ras mutations in patients with colorectal cancer: the multicenter ‘‘RASCAL” study. J Natl Cancer Inst 1998; 90: 675-84. doi: 10.1093/jnci/90.9.675AndreyevHJNormanARCunninghamDOatesJRClarkePAKirsten Ras mutations in patients with colorectal cancer: the multicenter ‘‘RASCAL” study1998906758410.1093/jnci/90.9.6759586664Open DOISearch in Google Scholar
Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study onthe PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 2010; 28: 466-74. doi: 10.1200/JCO.2009.23.3452RothADTejparSDelorenziMYanPFioccaRKlingbielDet alPrognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study onthe PETACC-3, EORTC 40993, SAKK 60-00 trial2010284667410.1200/JCO.2009.23.345220008640Open DOISearch in Google Scholar
Ogino S, Meyerhardt JA, Irahara N, Niedzwiecki D, Hollis D, Saltz LB, et al. KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. Clin Cancer Res 2009; 15: 7322-9. doi: 10.1158/1078-0432.CCR-09-1570OginoSMeyerhardtJAIraharaNNiedzwieckiDHollisDSaltzLBet alKRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 898032009157322910.1158/1078-0432.CCR-09-1570278768919934290Open DOISearch in Google Scholar
Karapetis CS, Khambata-Ford S, Jonker DJ, O’Callaghan CJ, Tu D, Tebbutt NC, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359: 1757-65. doi: 10.1056/NEJMoa0804385KarapetisCSKhambata-FordSJonkerDJO’CallaghanCJTuDTebbuttNCet alK-ras mutations and benefit from cetuximab in advanced colorectal cancer200835917576510.1056/NEJMoa080438518946061Open DOISearch in Google Scholar
De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010; 11: 753-62. doi: 10.1016/S1470-2045(10)70130-3De RoockWClaesBBernasconiDDe SchutterJBiesmansBFountzilasGet alEffects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis2010117536210.1016/S1470-2045(10)70130-320619739Open DOISearch in Google Scholar
Schiripa M, Cremolini C, Loupakis F, Morvillo M, Bergamo F, Zoratto F, et al. Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer. Int J Cancer 2015; 136: 83-90. doi: 10.1002/ijc.28955SchiripaMCremoliniCLoupakisFMorvilloMBergamoFZorattoFet alRole of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer2015136839010.1002/ijc.2895524806288Open DOISearch in Google Scholar
Au HJ, Karapetis CS, O’Callaghan CJ, Tu D, Moore MJ, Zalcberg JR, et al. Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: Overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 Trial. J Clin Oncol 2009; 27: 1822-8. doi: 10.1200/ JCO.2008.19.6048AuHJKarapetisCSO’CallaghanCJTuDMooreMJZalcbergJRet alHealth-related quality of life in patients with advanced colorectal cancer treated with cetuximab: Overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 Trial2009271822810.1200/ JCO.2008.19.6048Open DOISearch in Google Scholar
Matallanas D, Birtwistle M, Romano D, Zebisch A, Rauch J, von Kriegsheim A, et al. Raf family kinases: old dogs have learned new tricks. Genes Cancer 2011; 2: 232-60. doi: 10.1177/1947601911407323MatallanasDBirtwistleMRomanoDZebischARauchJvon KriegsheimAet alRaf family kinases: old dogs have learned new tricks201122326010.1177/1947601911407323312862921779496Open DOISearch in Google Scholar
Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, et al. Mechanism of activation of the RAF- ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004; 116: 855-67. doi: 10.1016/s0092-8674(04)00215-6WanPTGarnettMJRoeSMLeeSNiculescu-DuvazDGoodVMet alMechanism of activation of the RAF- ERK signaling pathway by oncogenic mutations of B-RAF20041168556710.1016/s0092-8674(04)00215-615035987Open DOISearch in Google Scholar
Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-54. doi: 10.1038/ nature00766DaviesHBignellGRCoxCStephensPEdkinsSCleggSet alMutations of the BRAF gene in human cancer20024179495410.1038/ nature00766Open DOISearch in Google Scholar
Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH, et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 2011; 377: 2103-14. doi: 10.1016/S0140-6736(11)60613-2MaughanTSAdamsRASmithCGMeadeAMSeymourMTWilsonRHet alAddition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial201137721031410.1016/S0140-6736(11)60613-2315941521641636Open DOISearch in Google Scholar
Souglakos J, Philips J, Wang R, Marwah S, Silver M, Tzardi M, et al. Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. Br J Cancer 2009; 101: 465-72. doi: 10.1038/sj.bjc.6605164SouglakosJPhilipsJWangRMarwahSSilverMTzardiMet alPrognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer20091014657210.1038/sj.bjc.6605164272023219603024Open DOISearch in Google Scholar
Richman SD, Seymour MT, Chambers P, Elliott F, Daly CL, Meade AM, et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from theMRC FOCUS trial. J Clin Oncol 2009; 27: 5931-7. doi: 10.1200/JCO.2009.22.4295RichmanSDSeymourMTChambersPElliottFDalyCLMeadeAMet alKRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from theMRC FOCUS trial2009275931710.1200/JCO.2009.22.429519884549Open DOISearch in Google Scholar
Tran B, Kopetz S, Tie J, Gibbs P, Jiang ZQ, Lieu CH, et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer 2011; 117: 4623-32. doi: 10.1002/cncr.26086TranBKopetzSTieJGibbsPJiangZQLieuCHet alImpact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer201111746233210.1002/cncr.26086425747121456008Open DOISearch in Google Scholar
Yokota T, Ura T, Shibata N, Takahari D, Shitara K, Nomura M, et al. BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer. Br J Cancer 2011; 104: 856-62. doi: 10.1038/bjc.2011.19YokotaTUraTShibataNTakahariDShitaraKNomuraMet alBRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer20111048566210.1038/bjc.2011.19304821021285991Open DOISearch in Google Scholar
Tie J, Gibbs P, Lipton L, Christie M, Jorissen RN, Burgess AW, et al. Optimizing targeted therapeutic develop- ment: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation. Int J Cancer 2011; 128: 207584. doi: 10.1002/ijc.25555TieJGibbsPLiptonLChristieMJorissenRNBurgessAWet alOptimizing targeted therapeutic develop- ment: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation201112820758410.1002/ijc.2555520635392Open DOISearch in Google Scholar
Li HT, Lu YY, An YX, Wang X, Zhao QC. KRAS, BRAF and PIK3CA mutations in human colorectal cancer: relationship with metastatic colorectal cancer. Oncol Rep 2011; 25: 1691-97. doi: 10.3892/or.2011.1217LiHTLuYYAnYXWangXZhaoQCKRAS, BRAF and PIK3CA mutations in human colorectal cancer: relationship with metastatic colorectal cancer20112516919710.3892/or.2011.121721424126Open DOISearch in Google Scholar
Hsieh LL, Er TK, Chen CC, Hsieh JS, Chang JG, Liu TC. Characteristics and prevalence of KRAS, BRAF, and PIK3CA mutations in colorectal cancer by high-resolution melting analysis in Taiwanese population. Clin Chim Acta 2012; 413: 1605-11. doi: 10.1016/j.cca.2012.04.029HsiehLLErTKChenCCHsiehJSChangJGLiuTCCharacteristics and prevalence of KRAS, BRAF, and PIK3CA mutations in colorectal cancer by high-resolution melting analysis in Taiwanese population201241316051110.1016/j.cca.2012.04.02922579930Open DOISearch in Google Scholar
Shen Y, Wang J, Han X, Yang H, Wang S, Lin D et al. Effectors of epidermal growth factor receptor pathway: the genetic profiling of KRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine. PLoS One 2013; 8: e81628. doi: 10.1371/journal.pone.0081628ShenYWangJHanXYangHWangSLinDet alEffectors of epidermal growth factor receptor pathway: the genetic profiling of KRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine20138e8162810.1371/journal.pone.0081628385824224339949Open DOISearch in Google Scholar
Lo L, Price T, Young J, Townsend A. BRAF mutation in colorectal cancer. [cited 10 Feb 2019]. Available at: https://www.intechopen.com/books/colorectal-cancer-from-pathogenesis-to-treatment/braf-mutation-in-colorectal-cancer doi: 10.5772/62226LoLPriceTYoungJTownsendA[cited 10 Feb 2019]. Available athttps://www.intechopen.com/books/colorectal-cancer-from-pathogenesis-to-treatment/braf-mutation-in-colorectal-cancer10.5772/62226Open DOISearch in Google Scholar
Kambara T, Simms LA, Whitehall VL, Spring KJ, Wynter CV, Walsh MD, et al. BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum. Gut 2004; 53: 1137-44. doi: 10.1136/gut.2003.037671KambaraTSimmsLAWhitehallVLSpringKJWynterCVWalshMDet alBRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum20045311374410.1136/gut.2003.037671177413015247181Open DOISearch in Google Scholar
Tran B, Kopetz S, Tie J, Gibbs P, Jiang ZQ, Lieu CH, et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer 2011; 117: 4623-32. doi: 10.1002/cncr.26086TranBKopetzSTieJGibbsPJiangZQLieuCHet alImpact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer201111746233210.1002/cncr.26086425747121456008Open DOISearch in Google Scholar
Chen D, Huang JF, Liu K, Zhang LQ, Yang Z, Chuai ZR, et al. BRAF V600E mutation and its association with clinicopathological features of colorectal cancer: a systematic review and meta-analysis. PLoS One 2014; 2014; 9: e90607. doi: 10.1371/journal.pone.0090607ChenDHuangJFLiuKZhangLQYangZChuaiZRet alBRAF V600E mutation and its association with clinicopathological features of colorectal cancer: a systematic review and meta-analysis201420149e9060710.1371/journal.pone.0090607394092424594804Open DOISearch in Google Scholar
Ogino S, Nosho K, Kirkner GJ, Shima K, Irahara N, Kure S, et al. PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. J Clin Oncol 2009; 27: 1477-84. doi: 10.1200/ JCO.2008.18.654OginoSNoshoKKirknerGJShimaKIraharaNKureSet alPIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer20092714778410.1200/ JCO.2008.18.654Open DOISearch in Google Scholar
Zarkavelis G, Boussiosa S, Papadakia A, Katsanos KH, Christodoulou DK, Pentheroudakis G. Current and future biomarkers in colorectal cancer. Ann Gastroenterol 2017; 30: 613-21. doi: 10.20524/aog.2017.0191ZarkavelisGBoussiosaSPapadakiaAKatsanosKHChristodoulouDKPentheroudakisGCurrent and future biomarkers in colorectal cancer2017306132110.20524/aog.2017.0191567028029118555Open DOISearch in Google Scholar
Imai K, Yamamoto H. Carcinogenesis and microsatellite instability: the interrelation- ship between genetics and epigenetics. Carcinogenesis 2008; 29: 673-80. doi: 10.1093/carcin/bgm228ImaiKYamamotoHCarcinogenesis and microsatellite instability: the interrelation- ship between genetics and epigenetics2008296738010.1093/carcin/bgm22817942460Open DOISearch in Google Scholar
Jensen LH, Lindebjerg J, Byriel L, Kolvraa S, Crüger DG. Strategy in clinical practice for classification of unselected colorectal tumours based on mismatch repair deficiency. Colorectal Dis 2008; 10: 490-7. doi: 10.1111/j.1463-1318.2007.01378.xJensenLHLindebjergJByrielLKolvraaSCrügerDGStrategy in clinical practice for classification of unselected colorectal tumours based on mismatch repair deficiency200810490710.1111/j.1463-1318.2007.01378.x17868408Open DOISearch in Google Scholar
Rahner N, Friedrichs N, Steinke V, Aretz S, Friedl W, Buettner R, et al. Coexisting somatic promoter hypermethylation and pathogenic MLH1 germline mutation in Lynch syndrome. J Pathol 2008; 214: 10-16. doi: 10.1002/path.2263RahnerNFriedrichsNSteinkeVAretzSFriedlWBuettnerRet alCoexisting somatic promoter hypermethylation and pathogenic MLH1 germline mutation in Lynch syndrome2008214101610.1002/path.226317973250Open DOISearch in Google Scholar
Domingo E, Laiho P, Ollikainen M, Pinto L, Wang A, French J, et al. BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. J Med Genet 2004; 41: 664-8. doi: 10.1136/jmg.2004.020651DomingoELaihoPOllikainenMPintoLWangAFrenchJet alBRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing200441664810.1136/jmg.2004.020651173588515342696Open DOISearch in Google Scholar
Cremolini C, Loupakis F, Antoniotti C, Lupi C, Sensi E, Lonardi S, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol 2015; 16: 1306-15. doi: 10.1016/S1470-2045(15)00122-9CremoliniCLoupakisFAntoniottiCLupiCSensiELonardiSet alFOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study20151613061510.1016/S1470-2045(15)00122-926338525Open DOISearch in Google Scholar
Sanz- Garcia E, Argiles G, Elez E, Tabernero J. BRAF mutant colorectal cancer: prognosis, treatment, and new perspectives. Ann Oncol 2017; 28: 2648-57. doi: 10.1093/annonc/mdx401Sanz-Garcia EArgilesGElezETaberneroJBRAF mutant colorectal cancer: prognosis, treatment, and new perspectives20172826485710.1093/annonc/mdx40129045527Open DOISearch in Google Scholar
Renaud S, Romain B, Falcoz PE, Olland A, Santelmo N, Brigand C, et al. KRAS and BRAF mutations are prognostic biomarkers in patients undergoing lung metastasectomy of colorectal cancer. Br J Cancer 2015; 112: 720-8. doi: 10.1038/bjc.2014.499RenaudSRomainBFalcozPEOllandASantelmoNBrigandCet alKRAS and BRAF mutations are prognostic biomarkers in patients undergoing lung metastasectomy of colorectal cancer2015112720810.1038/bjc.2014.499433348725688918Open DOISearch in Google Scholar
Bokemeyer C, Van Cutsem E, Rougier P, Ciardiello F, Heeger S, Schlichting, et al. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer 2012; 48: 1466-75. doi: 10.1016/j.ejca.2012.02.057BokemeyerCVanCutsem ERougierPCiardielloFHeegerSSchlichting, et alAddition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials20124814667510.1016/j.ejca.2012.02.05722446022Open DOISearch in Google Scholar
Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013; 369: 1023-34. doi: 10.1056/NEJMoa1305275DouillardJYOlinerKSSienaSTaberneroJBurkesRBarugelMet alPanitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer201336910233410.1056/NEJMoa130527524024839Open DOISearch in Google Scholar
Seymour MT, Brown SR, Middleton G, Maughan T, Richman S, Gwyther S, et al. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. Lancet Oncol 2013; 14: 749-59. doi: 10.1016/S1470-2045(13)70163-3SeymourMTBrownSRMiddletonGMaughanTRichmanSGwytherSet alPanitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial2013147495910.1016/S1470-2045(13)70163-3369971323725851Open DOISearch in Google Scholar
Karapetis CS, Jonker D, Daneshmand M, Hanson JE, O’Callaghan CJ, Marginean C, et al. PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer—results from NCIC CTG/AGITG CO.17. Clin Cancer Res 2014; 20: 744-53. doi: 10.1158/1078-0432.CCR-13-0606KarapetisCSJonkerDDaneshmandMHansonJEO’CallaghanCJMargineanCet alPIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer—results from NCIC CTG/AGITG CO.172014207445310.1158/1078-0432.CCR-13-060624218517Open DOISearch in Google Scholar
Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, et al. Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer. Ann Oncol 2014; 25: 107-16. doi: 10.1093/annonc/mdt523PeetersMPriceTJCervantesASobreroAFDucreuxMHotkoYet alFinal results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer2014251071610.1093/annonc/mdt52324356622Open DOISearch in Google Scholar
Pietrantonio F, Petrelli F, Coinu A, Di Bartolomeo M, Borgonovo K, Maggi C, et al. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis. Eur J Cancer 2015; 51: 587-94. doi: 10.1016/j.ejca.2015.01.054PietrantonioFPetrelliFCoinuADiBartolomeo MBorgonovoKMaggiCet alPredictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis2015515879410.1016/j.ejca.2015.01.05425673558Open DOISearch in Google Scholar
Rowland A, Dias MM, Wiese MD, Kichenadasse G, McKinnon RA, Karapetis CS, et al. Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer. Br J Cancer 2015; 112: 1888-94. doi: 10.1038/ bjc.2015.173RowlandADiasMMWieseMDKichenadasseGMcKinnonRAKarapetisCSet alMeta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer201511218889410.1038/ bjc.2015.173Open DOISearch in Google Scholar
Yuan ZX, Wang XY, Qin QY, Chen DF, Zhong QH, Wang L, et al. The prognostic role of BRAF mutation in metastatic colorectal cancer receiving anti-EGFR monoclonal antibodies: a meta-analysis. PLoS One 2013; 8: e65995. doi: 10.1371/journal.poneYuanZXWangXYQinQYChenDFZhongQHWangLet alThe prognostic role of BRAF mutation in metastatic colorectal cancer receiving anti-EGFR monoclonal antibodies: a meta-analysis20138e6599510.1371/journal.poneOpen DOISearch in Google Scholar
Loupakis F, Cremolini C, Salvatore L, Masi G, Sensi E, Schirripa M, et al. FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer. Eur J Cancer 2014; 50: 57-63. doi: 10.1016/j.ejcaLoupakisFCremoliniCSalvatoreLMasiGSensiESchirripaMet alFOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer201450576310.1016/j.ejcaOpen DOISearch in Google Scholar
Van Cutsem E, Huijberts S, Grothey A, Yaeger R, Cuyle PJ, Elez E, et al. BEACON CRC study safety lead-in (SLI) in patients with BRAF V600E metastatic colorectal cancer: Binimetinib, Encorafenib and Cetuximab Triplet Therapy for patients with BRAF V600E-mutant metastatic colorectal cancer: safety lead-in results from the phase III BEACON colorectal cancer study. J Clin Oncol 2019: 37: 1460-9. doi: 10.1200/JCO.18.02459VanCutsem EHuijbertsSGrotheyAYaegerRCuylePJElezEet alBEACON CRC study safety lead-in (SLI) in patients with BRAF V600E metastatic colorectal cancer: Binimetinib, Encorafenib and Cetuximab Triplet Therapy for patients with BRAF V600E-mutant metastatic colorectal cancer: safety lead-in results from the phase III BEACON colorectal cancer study2019371460910.1200/JCO.18.02459737069930892987Open DOISearch in Google Scholar
Schuell B, Gruenberger T, Scheithauer W, Zielinski Ch, Wrba F. HER 2/neu protein expression in colorectal cancer. BMC Cancer 2006; 6: 123. doi: 10.1186/1471-2407-6-123SchuellBGruenbergerTScheithauerWZielinskiChWrbaFHER 2/neu protein expression in colorectal cancer2006612310.1186/1471-2407-6-123147587616681853Open DOISearch in Google Scholar
Siena S, Sartore-Bianchi A, Marsoni S, Hurwitz HI, McCall SJ, Penault-Llorca F, et al. Targeting the human epidermal growth factor receptor 2 ( HER2) oncogene in colorectal cancer. Ann Oncol 2018; 29: 1108-19. doi: 10.1093/ annonc/mdy100SienaSSartore-BianchiAMarsoniSHurwitzHIMcCallSJPenault-LlorcaFet alTargeting the human epidermal growth factor receptor 2 ( HER2) oncogene in colorectal cancer20182911081910.1093/ annonc/mdy100Open DOISearch in Google Scholar
Seo AN, Kwak Y, Kim DW, Kang SB, Choe G, Kim WH, et al. Her2 status in colorectal cancer: its clinical significance and the relationship between HER2 gene amplification and expression. PLoS One 2014; 9: e98528. doi: 10.1371/journal.poneSeoANKwakYKimDWKangSBChoeGKimWHet alHer2 status in colorectal cancer: its clinical significance and the relationship between HER2 gene amplification and expression20149e9852810.1371/journal.poneOpen DOISearch in Google Scholar
Ingold Heppner B, Behrens HM, Balschun K, Haag J, Krüger S, Becker T, et al. HER2/neu testing in primary colorectal carcinoma. Br J Cancer 2014; 111: 1977-84. doi: 10.1038/bjc.2014.483IngoldHeppner BBehrensHMBalschunKHaagJKrügerSBeckerTet alHER2/neu testing in primary colorectal carcinoma201411119778410.1038/bjc.2014.483422962925211663Open DOISearch in Google Scholar
Missiaglia E, Jacobs B, D’Ario G, Di Narzo AF, Soneson C, Budinska E, et al. Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. Ann Oncol 2014; 25: 1995-2001. doi: 10.1093/annonc/ mdu275MissiagliaEJacobsBD’ArioGDiNarzo AFSonesonCBudinskaEet alDistal and proximal colon cancers differ in terms of molecular, pathological, and clinical features2014251995200110.1093/annonc/ mdu275Open DOISearch in Google Scholar
Nam SK, Yun S, Koh J, Kwak Y, Seo AN, Park KU, et al. BRAF, PIK3CA, and HER2 oncogenic alterations according to KRAS mutation status in advanced colorectal cancers with distant metastasis. PLoS One 2016; 11: e0151865. doi: 10.1371/journal.poneNamSKYunSKohJKwakYSeoANParkKUet alBRAF, PIK3CA, and HER2 oncogenic alterations according to KRAS mutation status in advanced colorectal cancers with distant metastasis201611e015186510.1371/journal.poneOpen DOISearch in Google Scholar
Bertotti A, Migliardi G, Galimi F, Sassi F, Torti D, Isella C, et al. A molecularly annotated platform of patient-derived xenografts (“Xenopatient”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discovery 2011; 1: 508-23. doi: 10.1158/2159-8290BertottiAMigliardiGGalimiFSassiFTortiDIsellaCet alA molecularly annotated platform of patient-derived xenografts (“Xenopatient”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer201115082310.1158/2159-8290Open DOISearch in Google Scholar
Yonesaka K, Zejnullahu K, Okamoto I, Satoh T, Cappuzzo F, Souglakos J, et al. Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med 2011; 3: 99ra86. doi: 10.1126/ scitranslmed.3002442YonesakaKZejnullahuKOkamotoISatohTCappuzzoFSouglakosJet alActivation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab2011399ra8610.1126/ scitranslmed.3002442Open DOISearch in Google Scholar
Martin V, Landi L, Molinari F, Fountzilas G, Geva R, Riva A, et al. HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients. Br J Cancer 2013; 108: 668-75. doi: 10.1038/bjc.2013MartinVLandiLMolinariFFountzilasGGevaRRivaAet alHER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients20131086687510.1038/bjc.2013Open DOISearch in Google Scholar
Osako T, Miyahara M, Uchino S, Inomata M, Kitano S, Kobayashi M. Immunohistochemical study of c-erbB-2 protein in colorectal cancer and the correlation with patient survival. Oncology 1998; 55: 548-55. doi: 10.1159/000011911OsakoTMiyaharaMUchinoSInomataMKitanoSKobayashiMImmunohistochemical study of c-erbB-2 protein in colorectal cancer and the correlation with patient survival1998555485510.1159/0000119119778622Open DOISearch in Google Scholar
Kapitanovic S, Radosevic S, Kapitanovic M, Andelinovic S, Ferencic Z, Tavassoli M, et al. The expression of p185(HER-2/neu) correlates with the stage of disease and survival in colorectal cancer. Gastroenterology 1997; 112: 1103-13. doi: 10.1016/S0016-5085(97)70120-3KapitanovicSRadosevicSKapitanovicMAndelinovicSFerencicZTavassoliMet alThe expression of p185(HER-2/neu) correlates with the stage of disease and survival in colorectal cancer199711211031310.1016/S0016-5085(97)70120-3Open DOISearch in Google Scholar
Li C, Liu DR, Ye LY, Huang LN, Jaiswai S, Li XW, et al. HER-2 overexpression and survival in colorectal cancer: a meta-analysis. J Zhejiang Univ Sci B 2014; 15: 582-9. doi: 10.1631/jzus.B1300258LiCLiuDRYeLYHuangLNJaiswaiSLiXWet alHER-2 overexpression and survival in colorectal cancer: a meta-analysis201415582910.1631/jzus.B1300258411685524903996Open DOISearch in Google Scholar
Zhang L. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part II. The utility of microsatellite instability testing. J Mol Diagn 2008; 10: 301-7. doi: 10.2353/jmoldx.2008.080062ZhangLImmunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome200810301710.2353/jmoldx.2008.080062243819718556776Open DOISearch in Google Scholar
Ward R, Meagher A, Tomlinson I, O’Connor T, Norrie M, Wu R, et al. Microsatellite instability and the clinicopathological features of sporadic colorectal cancer. Gut 2001; 48: 821-9. doi: 10.1136/gut.48.6.821WardRMeagherATomlinsonIO’ConnorTNorrieMWuRet alMicrosatellite instability and the clinicopathological features of sporadic colorectal cancer200148821910.1136/gut.48.6.821172832411358903Open DOISearch in Google Scholar
Tiwari AK, Roy HK, Lynch HT. Lynch syndrome in the 21st century: clinical perspectives. QJM 2016; 109: 151-8. doi: 10.1093/qjmed/hcv137TiwariAKRoyHKLynchHTLynch syndrome in the 21st century: clinical perspectives2016109151810.1093/qjmed/hcv13726224055Open DOISearch in Google Scholar
Ashktorab H, Ahuja S, Kannan L, Lior X, Ellis NA, Xicola RM, et al. A meta-analysis of MSI frequency and race in colorectal cancer. Oncotarget 2016; 7: 34546-57. doi: 10.18632/oncotarget.8945AshktorabHAhujaSKannanLLiorXEllisNAXicolaRMet alA meta-analysis of MSI frequency and race in colorectal cancer20167345465710.18632/oncotarget.8945508517527120810Open DOISearch in Google Scholar
Overman MJ, Lonardi S, Wong KYM, Lenz HJ, Gelsomino F, Aglietta M, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol 2018; 36: 773-9. doi: 10.1200/JCO.2017.76.9901OvermanMJLonardiSWongKYMLenzHJGelsominoFAgliettaMet alDurable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer201836773910.1200/JCO.2017.76.990129355075Open DOISearch in Google Scholar
Fujiyoshi K, Yamamoto G, Takenoya T, Takahashi A, Arai Y, Yamada M, et al. Metastatic pattern of stage IV colorectal cancer with high-frequency micro-satellite instability as a prognostic factor. Anticancer Res 2017; 37: 239-47. doi: 10.21873/anticanres.11313FujiyoshiKYamamotoGTakenoyaTTakahashiAAraiYYamadaMet alMetastatic pattern of stage IV colorectal cancer with high-frequency micro-satellite instability as a prognostic factor2017372394710.21873/anticanres.1131328011498Open DOISearch in Google Scholar
Kawakami H, Zaanan A, Sinicrope FA. MSI testing and its role in management of colorectal cancer. Curr Treat Options Oncol 2015; 16: 30. doi: 10.1007/s11864-015-0348-2KawakamiHZaananASinicropeFAMSI testing and its role in management of colorectal cancer2015163010.1007/s11864-015-0348-2459419026031544Open DOISearch in Google Scholar